Mar. 11 at 10:09 AM
$KZIA The scale and upside here - is best highlighted by a review of the pipeline of the only other dual acting PI3K mTOR drug in development. Celcuity claim likely future sales of
$10 b - but their drug is ineffective in crossing what is known as the blood brain barrier. Paxalisib has apparent ability to work in the brain and to destroy primary cancers & brain metastasis. - such to achieve much broader effectiveness and worth, compared with Celcuity. See their pipeline which highlight new standard of care treatment options, for these major cancers. Paxalisib is a drug with enormous worth, with strong potential to outperform Celcuity.
